Our vision is to be the accepted PAIONeer in sedation and anesthesia; helping advance patient care.
PAION is committed to developing medical innovations in procedural sedation, anesthesia and intensive care. Our lead compound is Remimazolam, which is currently in Phase III clinical development.
PAION has concluded a number of successful commercialization partnerships for Remimazolam in selected markets and plans to enter into additional license agreements. Thanks to our successful “string of pearls”-strategy, we are able to extend our international reach with high-profile national champions in the therapeutic domain.
PAION is not actively involved in the development of GGF2 and M6G, but instead benefits from future milestone payments and royalties.